Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620609
Title:
Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres.
Authors:
Sanganalmath, P; Lester, J E; Bradshaw, A G; Das, T; Esler, C; Roy, A E F; Toy, Elizabeth; Lester, J F; Button, M; Wilson, P; Comins, C; Atherton, P; Pickles, R; Foweraker, K; Walker, G A; Keni, M; Hatton, M Q
Abstract:
Continuous hyperfractionated accelerated radiotherapy (CHART) remains an option to treat non-small cell lung cancer (NSCLC; NICE, 2011). We have previously published treatment outcomes from 1998-2003 across five UK centres. Here we update the UK CHART experience, reporting outcomes and toxicities for patients treated between 2003 and 2009.
Citation:
Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres. 2018 Clin Oncol (R Coll Radiol)
Publisher:
Elsevier
Journal:
Clinical oncology (Royal College of Radiologists (Great Britain))
Issue Date:
11-Jan-2018
URI:
http://hdl.handle.net/11287/620609
DOI:
10.1016/j.clon.2017.12.019
PubMed ID:
29336865
Additional Links:
http://linkinghub.elsevier.com/retrieve/pii/S0936-6555(17)30541-1
Type:
Journal Article
Language:
en
ISSN:
1433-2981
Appears in Collections:
Oncology; 2018 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSanganalmath, Pen
dc.contributor.authorLester, J Een
dc.contributor.authorBradshaw, A Gen
dc.contributor.authorDas, Ten
dc.contributor.authorEsler, Cen
dc.contributor.authorRoy, A E Fen
dc.contributor.authorToy, Elizabethen
dc.contributor.authorLester, J Fen
dc.contributor.authorButton, Men
dc.contributor.authorWilson, Pen
dc.contributor.authorComins, Cen
dc.contributor.authorAtherton, Pen
dc.contributor.authorPickles, Ren
dc.contributor.authorFoweraker, Ken
dc.contributor.authorWalker, G Aen
dc.contributor.authorKeni, Men
dc.contributor.authorHatton, M Qen
dc.date.accessioned2018-02-08T15:34:59Z-
dc.date.available2018-02-08T15:34:59Z-
dc.date.issued2018-01-11-
dc.identifier.citationContinuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres. 2018 Clin Oncol (R Coll Radiol)en
dc.identifier.issn1433-2981-
dc.identifier.pmid29336865-
dc.identifier.doi10.1016/j.clon.2017.12.019-
dc.identifier.urihttp://hdl.handle.net/11287/620609-
dc.description.abstractContinuous hyperfractionated accelerated radiotherapy (CHART) remains an option to treat non-small cell lung cancer (NSCLC; NICE, 2011). We have previously published treatment outcomes from 1998-2003 across five UK centres. Here we update the UK CHART experience, reporting outcomes and toxicities for patients treated between 2003 and 2009.en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttp://linkinghub.elsevier.com/retrieve/pii/S0936-6555(17)30541-1en
dc.rightsArchived with thanks to Clinical oncology (Royal College of Radiologists (Great Britain))en
dc.subjectWessex Classification Subject Headings::Oncology. Pathology.en
dc.titleContinuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres.en
dc.typeJournal Articleen
dc.identifier.journalClinical oncology (Royal College of Radiologists (Great Britain))en
dc.type.versionIn press (epub ahead of print)en

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.